Phase I trial: the use of autologous cultured adipose-derived stroma/stem cells to treat patients with non-revascularizable critical limb ischemia.
Bura A., Planat-Benard V., Bourin P., Silvestre JS., Gross F., Grolleau JL.
Clinical Trial on Ankle Injury, Peripheral Artery Disease, Chronic Wound, published in Cytotherapy (2014) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Clinical Trial
- Journal
- Cytotherapy (2014)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 24438903
- DOI
- 10.1016/j.jcyt.2013.11.011
Abstract (original English)
Non-revascularizable critical limb ischemia (CLI) is the most severe stage of peripheral arterial disease, with no therapeutic option. Extensive preclinical studies have demonstrated that adipose-derived stroma cell (ASC) transplantation strongly improves revascularization and tissue perfusion in ischemic limbs. This study, named ACellDREAM, is the first phase I trial to evaluate the feasibility and safety of intramuscular injections of autologous ASC in non-revascularizable CLI patients. Seven patients were consecutively enrolled, on the basis of the following criteria: (i) lower-limb rest pain or ulcer; (ii) ankle systolic oxygen pressure <50 or 70 mm Hg for non-diabetic and diabetic patients, respectively, or first-toe systolic oxygen pressure <30 mm Hg or 50 mm Hg for non-diabetic and diabetic patients, respectively; (iii) not suitable for revascularization. ASCs from abdominal fat were grown for 2 weeks and were then characterized. More than 200 million cells were obtained, with almost total homogeneity and no karyotype abnormality. The expressions of stemness markers Oct4 and Nanog were very low, whereas expression of telomerase was undetectable in human ASCs compared with human embryonic stem cells. ASCs (10(8)) were then intramuscularly injected into the ischemic leg of patients, with no complication, as judged by an independent committee. Trans-cutaneous oxygen pressur
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewPubMed
Cell-Based Therapies for Post-Traumatic Ankle Osteoarthritis and Osteochondral Lesions of the Talus: A Systematic Scoping Review of an Emerging and Heterogeneous Evidence Base.
Systematic Review on Knee Osteoarthritis, Osteoarthritis, Cartilage Damage, Ankle Injury, published in Bioengineering (Basel) (2026) — summary generated from the PubMed abstract.
- 2026
Bioengineering (Basel) - Level ASystematic ReviewPubMed
Platelet-Rich Plasma Injections for Foot and Ankle Pathologies Have Significantly More Complications Compared With Hyaluronic Acid Injections, Saline Solution Injections, and Dry Needling: A Systematic Review.
Systematic Review with a reported sample of 674 on Osteoarthritis, Cartilage Damage, Tendon Injury, Ankle Injury, published in Arthroscopy (2025) — summary generated from the PubMed abstract.
- 2025
- n = 674
Arthroscopy1 citations - Level ASystematic ReviewEurope PMC
Operative management of osteochondral lesions of the talus: 2024 recommendations of the working group 'clinical tissue regeneration' of the German Society of Orthopedics and Traumatology (DGOU)
Systematic Review on Cartilage Damage, Ankle Injury, published in EFORT Open Rev (2024) — summary generated from the PubMed abstract.
- 2024
EFORT Open Rev23 citations - Level AMeta-analysisPubMed
Therapeutic Effect of Stem Cells from Different Sources on Diabetic Foot Ulcers: Systematic Review and Network Meta-Analysis.
Meta-analysis on Ankle Injury, Diabetic Foot, Chronic Wound, published in Int J Low Extrem Wounds (2024) — summary generated from the PubMed abstract.
- 2024
Int J Low Extrem Wounds - Level ASystematic ReviewEurope PMC
Visualized trends and bibliometric analysis in ankle cartilage repair from 2004 to 2024
Systematic Review on Cartilage Damage, Ankle Injury, published in Front Med (Lausanne) (2024) — summary generated from the PubMed abstract.
- 2024
Front Med (Lausanne) - Level ASystematic ReviewPubMed
Adipose-derived stem cells applied to ankle pathologies: a systematic review.
Systematic Review on Osteoarthritis, Cartilage Damage, Ankle Injury, Scar, published in Musculoskelet Surg (2023) — summary generated from the PubMed abstract.
- 2023
Musculoskelet Surg2 citations